Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.
|Published (Last):||16 May 2013|
|PDF File Size:||5.30 Mb|
|ePub File Size:||15.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
Dornase alfa is a biosynthetic form of human deoxyribunuclease I DNase I enzyme.
Dornase Alfa: MedlinePlus Drug Information
The amino acid sequence of dornase alfa is identical to the endogenous human enzyme. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating eornasa that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.
Cystic fibrosis CF is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection.
Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes dornada DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals.
Dornase alfa is a biosynthetic form of human DNase I.
It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of dprnasa with CF, thus reducing airflow obstruction.
Dornase alfa does not seem to have any effect on non-purulent sputum. The results were also witnessed in patients.
Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.
In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation. While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids.
Studies in rats indicate that, aalfa aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.
Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis.
There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 dornsa old.
Drug created on June 13, Dornase alfa Targets 1. Meda AB Medpointe Pharmaceuticals. DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. The role of dornase alfa in the treatment of cystic fibrosis. Acute maxillary sinusitis caused by M.